PEBC MCQ sample questions with answers and rationales

Correct answer: B. Perindopril 4 mg once daily

Step 1: An ACR of 18 mg/mmol exceeds the microalbuminuria threshold (>2.0 mg/mmol in men), confirming diabetic kidney involvement — this has to be recognized from the lab value itself, since it is not labeled for you. Step 2: Diabetes Canada and Hypertension Canada recommend an ACE inhibitor or ARB as first-line therapy whenever diabetic nephropathy/albuminuria is present, independent of baseline blood pressure, because RAAS blockade slows progression of kidney disease. Step 3: The potassium of 5.1 mmol/L is only mildly elevated and is NOT a contraindication to starting an ACE inhibitor — Canadian guidance calls for caution and a recheck of potassium/creatinine 1-2 weeks after initiation, but reserves avoidance of RAAS blockade for potassium above roughly 5.5 mmol/L or a rising trend on therapy. Step 4: Perindopril is therefore the correct first-line choice, with a plan to recheck labs shortly after starting.

• A. A test-taker might default to a thiazide as the "usual" first-line hypertension agent, but thiazides do not slow diabetic kidney disease progression the way RAAS blockade does, so they are not preferred once albuminuria is present.
• B. Correct: the elevated ACR signals diabetic nephropathy, which makes an ACE inhibitor first-line regardless of blood pressure; the mild potassium elevation (5.1 mmol/L) warrants monitoring, not avoidance.
• C. A test-taker might choose amlodipine to sidestep the potassium value entirely, but amlodipine does not slow albuminuria progression and is appropriate as an add-on, not a substitute for a RAAS inhibitor.
• D. A test-taker might reach for a beta-blocker as a generic cardioprotective choice, but beta-blockers are reserved for compelling cardiac indications (post-MI, reduced ejection fraction), not uncomplicated diabetic hypertension with nephropathy.

Key pearl: For diabetic patients with hypertension and albuminuria, prioritize an ACE inhibitor or ARB; mild hyperkalemia (<5.5 mmol/L) calls for monitoring, not avoidance of the drug class.

Reference: Hypertension Canada 2024 / Diabetes Canada Clinical Practice Guidelines

Correct answer: B. Apixaban 2.5 mg orally twice daily

Step 1: Apply the three apixaban dose-reduction criteria for NVAF: age ≥ 80 years, body weight ≤ 60 kg, and serum creatinine ≥ 133 µmol/L. Step 2: Check each criterion individually rather than eyeballing the case — age 82 meets the criterion; weight 61 kg does NOT meet the ≤ 60 kg threshold; serum creatinine 142 µmol/L meets the criterion. Step 3: The patient meets 2 of the 3 criteria (age and creatinine), which is sufficient to trigger the reduced dose — meeting all three is not required, only "at least two." Step 4: Apixaban 2.5 mg BID is therefore the correct dose.

• A. A test-taker who sees "elderly, low body weight, high creatinine" might assume full dose is still needed to preserve efficacy, but meeting 2 of the 3 reduction criteria mandates the lower dose regardless of apparent frailty.
• B. Correct: age (82) and serum creatinine (142 µmol/L) each independently meet a reduction criterion, satisfying the "at least 2 of 3" rule even though her weight of 61 kg narrowly misses the ≤ 60 kg cutoff.
• C. A test-taker might assume once-daily dosing simplifies adherence in an elderly patient, but apixaban requires twice-daily dosing in both the standard and reduced-dose NVAF regimens.
• D. A test-taker might recall "10 mg" from acute VTE dosing and misapply it here, but 10 mg BID is the VTE loading dose, not a stroke-prevention regimen for atrial fibrillation.

Key pearl: Apixaban NVAF dose reduction requires only 2 of 3 criteria (age ≥ 80, weight ≤ 60 kg, SCr ≥ 133 µmol/L) — check each threshold precisely; meeting all three is not required.

Reference: CCS Atrial Fibrillation Guidelines / Thrombosis Canada

Correct answer: B. Empagliflozin 10 mg once daily

Step 1: Identify the dominant clinical issue driving the choice of second agent — established atherosclerotic cardiovascular disease (prior MI), which Diabetes Canada guidelines treat as the key factor in agent selection, separate from the A1c target itself. Step 2: Among the options, only Empagliflozin (an SGLT2 inhibitor) has trial-proven reduction in cardiovascular mortality and heart failure hospitalization (EMPA-REG OUTCOME) in patients with established ASCVD. Step 3: Her recurrent genital mycotic infections are a recognized, manageable SGLT2-inhibitor side effect, treatable with antifungal therapy and hygiene counselling — this is a monitoring point, not a reason to withhold a drug class with proven mortality benefit in ASCVD. Step 4: Empagliflozin is therefore the most appropriate addition.

• A. A test-taker focused only on her A1c of 8.8% might reach for a potent glucose-lowering sulfonylurea, but gliclazide carries hypoglycemia and weight-gain risk with no proven cardiovascular benefit, missing her real priority: established ASCVD.
• B. Correct: empagliflozin has proven mortality and heart-failure benefit in ASCVD, and her recurrent yeast infections are a manageable, counselling-responsive side effect, not a reason to withhold a cardioprotective agent.
• C. A test-taker might favour sitagliptin specifically because it avoids genital infection risk, but DPP-4 inhibitors are cardiovascular-neutral and do not address her ASCVD-driven need for proven benefit.
• D. A test-taker might pick pioglitazone for its insulin-sensitizing effect in an obese patient, but TZDs cause fluid retention and are relatively avoided in patients with cardiovascular disease due to heart-failure risk.

Key pearl: For T2DM with established ASCVD, select an SGLT2 inhibitor or GLP-1 receptor agonist for proven CV benefit; a manageable side effect like genital mycotic infection should not override this priority.

Reference: Diabetes Canada Clinical Practice Guidelines - Pharmacotherapy for Type 2 Diabetes

Correct answer: A. 14 days when stored in a refrigerator (2°C to 8°C)

Step 1: Check whether any published stability data apply specifically to this exact formulation — the only reference found describes a different vehicle and concentration, so it is not applicable here; stability data from a different recipe cannot be borrowed for this one. Step 2: Because no formulation-specific stability data exist, the NAPRA/USP <795> default BUD limits apply instead. Step 3: This is a water-containing oral liquid, for which the default maximum BUD is 14 days, and only when stored under refrigeration (2-8°C). Step 4: 14 days refrigerated is therefore the correct maximum BUD and storage condition.

• A. Correct: with no stability data applicable to this exact formulation, the default BUD for a water-containing oral liquid is 14 days, and only if refrigerated.
• B. A test-taker might recall "30 days room temperature" as a general compounding BUD figure, but that applies to water-containing topical/mucosal preparations, not oral liquids.
• C. A test-taker might misapply the unrelated tertiary reference's stability window, but that data describes a different vehicle and concentration and cannot be transferred to this formulation.
• D. A test-taker might feel an infant formulation warrants extra caution and under-assign a 24-hour BUD, but this is unnecessarily restrictive — the standard default for a refrigerated water-containing oral liquid is 14 days.

Key pearl: Apply formulation-specific stability data only when the vehicle AND concentration match exactly; otherwise default NAPRA/USP <795> BUDs apply: water-containing oral = 14 days refrigerated; water-containing topical = 30 days room temp; non-aqueous = 6 months.

Reference: NAPRA Model Standards for Pharmacy Compounding of Non-Sterile Preparations / USP <795>

Correct answer: A. Tallman lettering (hydroMORPHONE/MORPHine) plus physical separation of the two drugs in storage

Step 1: ISMP Canada's approach to LASA high-alert drug pairs layers multiple independent safeguards rather than relying on any single measure. Step 2: Tallman lettering (e.g., hydroMORPHONE vs. MORPHine) visually breaks the pattern-matching that causes look-alike name confusion. Step 3: Physical separation in storage removes the proximity that lets a rushed selection grab the wrong vial. Step 4: Using tallman lettering together with physical separation is the recommended combined strategy — using only one measure in isolation leaves a meaningful gap in protection.

• A. Correct: ISMP Canada recommends combining tallman lettering with physical separation of look-alike high-alert opioids, since either measure alone leaves a residual risk that the other closes.
• B. A test-taker might think tallman lettering alone is sufficient, but without physical separation the vials remain stored together, so a rushed selection can still default to familiar shape or position rather than reading the label.
• C. A test-taker might think bigger text improves safety, but uniformly enlarging both names without changing letter emphasis does nothing to break the visual similarity that causes LASA confusion.
• D. A test-taker might rely on a double-check at the bedside as the main safeguard, but this addresses only administration, not the selection error that occurs earlier during storage and picking.

Key pearl: ISMP Canada high-alert LASA mitigation works best as layered safeguards: tallman lettering AND physical separation AND independent double-checks — no single measure alone is considered sufficient.

Reference: ISMP Canada High-Alert Medication Safety Guidelines

Correct answer: A. Yes — verbal narcotic prescriptions are permitted under the CSR with complete documentation

Step 1: Classify the drug — Percocet (oxycodone/acetaminophen) is a "straight narcotic." Step 2: Recall which rule applies to verbal orders for straight narcotics — under the former Narcotic Control Regulations (NCR), straight narcotics could never be accepted verbally, but that restriction no longer applies. Step 3: The Controlled Substances Regulations (CSR), in force since October 1, 2026, permit a practitioner to issue a verbal prescription for any narcotic, including straight narcotics, directly to the pharmacist. Step 4: The pharmacist must record the drug, strength, directions, quantity, prescriber identity, and date/time before dispensing, but no written or faxed duplicate, and no supply-duration cap, is required.

• A. Correct: the CSR (effective October 1, 2026) removed the old written-only requirement for straight narcotics, so a complete, fully-documented verbal order for Percocet is legally sufficient before dispensing.
• B. A test-taker might recall the old Narcotic Control Regulations rule that straight narcotics required a written prescription, but the CSR replaced that framework and now permits verbal orders for all narcotics, including straight narcotics.
• C. A test-taker might assume a verbal narcotic order is only acceptable for a short "bridge" supply, but the CSR imposes no supply-duration limit on a properly documented verbal narcotic order.
• D. A test-taker might think a faxed written duplicate is still required as a safeguard, but under the CSR a complete verbal order can be dispensed against directly without a follow-up written copy.

Key pearl: Since the CSR took effect October 1, 2026, verbal orders are permitted for ALL narcotics, including straight/single-entity narcotics like oxycodone, hydromorphone, morphine, and fentanyl — the old written-only rule for straight narcotics no longer applies.

Reference: Controlled Substances Regulations (CSR), SOR/2025-242, effective October 1, 2026 (Health Canada)

Correct answer: C. It may be transferred more than once, within 2 years of receipt

Step 1: Recall the former rule — under the former Benzodiazepines and Other Targeted Substances Regulations (BOTSR), a targeted substance prescription could be transferred only once. Step 2: Recognize that the Controlled Substances Regulations (CSR), in force since October 1, 2026, removed that one-time limit. Step 3: A prescription for a targeted substance (e.g., lorazepam, clonazepam, temazepam, zopiclone) may now be transferred more than once — this Calgary-to-Vancouver transfer is legal even though it was already transferred once before. Step 4: Each transfer must still be completed within 2 years of the date the prescription was first received, through direct pharmacist-to-pharmacist verification, with the transferring pharmacy voiding its own remaining refill record.

• A. A test-taker might assume any re-transfer is automatically blocked once a prescription has already moved between pharmacies, but the CSR specifically removed the old one-transfer limit for targeted substances.
• B. A test-taker might recall the former BOTSR "one transfer only" rule and apply it here, but that limit no longer exists under the CSR (effective October 1, 2026).
• C. Correct: the CSR allows a targeted substance prescription to be transferred more than once, provided each transfer occurs within 2 years of when the prescription was first received.
• D. A test-taker might assume removing the transfer-count limit means transfers are unlimited in time as well, but the CSR still caps every transfer at within 2 years of the original prescription date.

Key pearl: Since the CSR (Oct 1, 2026), targeted substance AND narcotic prescriptions can be transferred more than once between pharmacies — the old one-time-only rule is gone — as long as each transfer is within 2 years of the original prescription and stays pharmacist-to-pharmacist.

Reference: Controlled Substances Regulations (CSR), SOR/2025-242, effective October 1, 2026 (Health Canada) — replaced BOTSR

Correct answer: B. Refuse to disclose any personal health information without the minor's consent

Step 1: Assess capacity — she demonstrated clear understanding of the risks, benefits, and use of the medication, which establishes her as a "mature minor" under Canadian law. Step 2: Apply the mature minor doctrine — an adolescent with capacity to consent to their own care is entitled to the same confidentiality as an adult patient, independent of age. Step 3: Because she has not consented to disclosure, the pharmacist cannot share any dispensing information, including partial information, with her mother. Step 4: The pharmacist must decline to confirm or deny any dispensing to the mother without the patient's explicit consent.

• A. A test-taker might assume a parent is automatically entitled to a minor's health information, but a mature minor who understands the treatment has the same confidentiality rights as an adult patient.
• B. Correct: because she demonstrated capacity to understand the risks, benefits, and use of the medication, she is a mature minor with full confidentiality rights — the pharmacist cannot disclose without her consent.
• C. A test-taker might think confirming only the drug name (without the indication) is a safe partial disclosure, but confirming any dispensing event to a third party without consent still breaches the mature minor's privacy.
• D. A test-taker might treat a minor requesting emergency contraception as inherently a protection concern, but seeking contraception is not, by itself, grounds for a child-protection referral.

Key pearl: Mature minors who understand treatment risks and benefits have full autonomy and confidentiality rights under Canadian health privacy law, even against a parent's direct request.

Reference: NAPRA Model Standards of Practice / Canadian Health Privacy Legislation (PIPEDA)

Correct answer: B. 50 mL/min

In Canadian SI units (serum creatinine in µmol/L): Formula for males: CrCl (mL/min) = [(140 - Age) * Weight (kg) * 1.2] / Serum Creatinine (µmol/L) Step 1: 140 - 68 = 72 Step 2: 72 * 70 kg * 1.2 = 6,048 Step 3: 6,048 / 120 µmol/L = 50.4 mL/min. Therefore, the calculated CrCl is approximately 50 mL/min.

• A. A test-taker might mistakenly apply the female correction factor (1.04) to a male patient, which under-calculates clearance to 42 mL/min instead of using the correct male factor of 1.2.
• B. Correct: using the male Cockcroft-Gault formula, (140 - 68) × 70 × 1.2 ÷ 120 = 50.4 mL/min, rounding to 50 mL/min.
• C. A test-taker might make a rounding or multiplication slip partway through the calculation, overestimating clearance to 62 mL/min.
• D. A test-taker might forget to subtract age from 140 before multiplying, which inflates the numerator and overestimates clearance to 74 mL/min.

Key pearl: Cockcroft-Gault in SI Units (µmol/L): Male = [(140 - Age) * Wt(kg) * 1.2] / SCr; Female = [(140 - Age) * Wt(kg) * 1.04] / SCr.

Reference: Cockcroft-Gault Equation (Canadian SI Units Handbook for Pharmacists)

Correct answer: A. 111 mL

Alligation Alternate Method: High concentration: 50% -> parts needed = |15 - 5| = 10 parts of 50% dextrose. Low concentration: 5% -> parts needed = |50 - 15| = 35 parts of 5% dextrose. Total parts = 10 + 35 = 45 parts. Fraction of 50% dextrose needed = 10 / 45. Volume of 50% solution needed = (10 / 45) * 500 mL = 111.1 mL (approximately 111 mL). Volume of 5% solution needed = (35 / 45) * 500 mL = 388.9 mL.

• A. Correct: using alligation alternate, parts of 50% solution = |15 - 5| = 10 of 45 total parts, so volume = (10/45) × 500 mL = 111 mL.
• B. A test-taker might misassign which concentration difference belongs to which stock solution, inverting the "parts," which leads to an incorrect 150 mL answer.
• C. A test-taker might double-count or miscalculate the total parts, arriving at 222 mL instead of the correct 111 mL.
• D. A test-taker might calculate the parts correctly but report the volume of the 5% solution (35/45 × 500 = 389 mL) instead of the 50% solution the question actually asks for.

Key pearl: Alligation Alternate: Parts of high = |Target - Low|; Parts of low = |High - Target|; Total parts = Sum. Multiply fraction by total volume — and double check which stock solution the question is asking about.

Reference: Pharmaceutical Calculations (Alligation Alternate)